ATE448301T1 - Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten - Google Patents

Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten

Info

Publication number
ATE448301T1
ATE448301T1 AT01984591T AT01984591T ATE448301T1 AT E448301 T1 ATE448301 T1 AT E448301T1 AT 01984591 T AT01984591 T AT 01984591T AT 01984591 T AT01984591 T AT 01984591T AT E448301 T1 ATE448301 T1 AT E448301T1
Authority
AT
Austria
Prior art keywords
proteins
repeat
collection
repetitive sequence
repeating sequences
Prior art date
Application number
AT01984591T
Other languages
English (en)
Inventor
Michael Stumpp
Patrick Forrer
Hans Binz
Andreas Plueckthun
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE448301T1 publication Critical patent/ATE448301T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01984591T 2000-09-08 2001-09-10 Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten ATE448301T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119670 2000-09-08
PCT/EP2001/010454 WO2002020565A2 (en) 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules

Publications (1)

Publication Number Publication Date
ATE448301T1 true ATE448301T1 (de) 2009-11-15

Family

ID=8169793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984591T ATE448301T1 (de) 2000-09-08 2001-09-10 Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten

Country Status (10)

Country Link
US (4) US7417130B2 (de)
EP (2) EP1332209B1 (de)
JP (3) JP5291279B2 (de)
AT (1) ATE448301T1 (de)
AU (1) AU2002218166A1 (de)
CA (1) CA2421447C (de)
DE (1) DE60140474D1 (de)
DK (1) DK1332209T3 (de)
ES (1) ES2335861T3 (de)
WO (1) WO2002020565A2 (de)

Families Citing this family (455)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007521832A (ja) * 2004-09-07 2007-08-09 クロネックス・ディベロップメント・インコーポレイテッド 細胞培養からのタンパク質収量の増加において使用するための細胞株
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
AU2015203464B2 (en) * 2006-02-13 2017-08-10 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
AR059448A1 (es) 2006-02-13 2008-04-09 Divergence Inc Polipeptidos quimericos vegetales de union para el reconocimiento molecular universal
AU2013201171B2 (en) * 2006-02-13 2016-01-21 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
US7897568B2 (en) 2006-03-03 2011-03-01 Vinay K. Singh Compositions for treatment of cancer
BRPI0710971A2 (pt) 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP5207222B2 (ja) * 2006-11-17 2013-06-12 独立行政法人農業生物資源研究所 ロイシンリッチリピート（ｌｒｒ）配列等反復配列を利用したタンパク質の作製方法
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
WO2008127680A2 (en) * 2007-04-11 2008-10-23 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
EP2164961B1 (de) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
US20100317599A1 (en) * 2008-02-13 2010-12-16 Alrik Pieter Los Process for the production of a peptide
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
EP2103936A1 (de) * 2008-03-19 2009-09-23 Institut Pasteur Reagenzfreie fluoreszierende Biosensoren mit einem konstruierten Ankyrin-Wiederholungsmodul und Verfahren zu ihrer Konstruktion und Verwendung
WO2009115919A2 (en) * 2008-03-19 2009-09-24 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2271323A2 (de) 2008-05-06 2011-01-12 Glaxo Group Limited Einkapselung biologischer wirkstoffe
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
EP2316030B1 (de) 2008-07-25 2019-08-21 Wagner, Richard W. Proteinscreeningverfahren
WO2010021720A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Conjugates of small-interfering nucleic acids
BRPI0921469B1 (pt) * 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (de) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalente und/oder multispezifische rankl-bindende konstrukte
AU2010217120B2 (en) * 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CN102341412B (zh) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2459053A2 (de) 2009-07-28 2012-06-06 F. Hoffmann-La Roche AG Nicht invasives optisches in-vivo-bildgebungsverfahren
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
WO2011072266A2 (en) 2009-12-11 2011-06-16 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
PE20170687A1 (es) 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN102939538A (zh) 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP3974453A3 (de) 2010-11-16 2022-08-03 Amgen Inc. Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
TWI504609B (zh) 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
WO2012093704A1 (ja) 2011-01-07 2012-07-12 中外製薬株式会社 抗体の物性を改善させる方法
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
JP5826863B2 (ja) 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EA201391607A1 (ru) * 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
ES2704007T3 (es) 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
SI3498732T1 (sl) 2011-05-06 2022-04-29 Zoetis Services Llc Protitelesa proti živčnemu rastnemu faktorju ter postopki za pripravo in uporabo le-teh
GB2504887B (en) 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2718326B1 (de) 2011-06-13 2020-08-19 CSL Limited Antikörper gegen g-csfr und verwendungen davon
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
KR102276528B1 (ko) 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2752200B1 (de) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur induzierung einer immunantwort auf ein zielantigen
JP6271251B2 (ja) 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2013074840A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP2612916A1 (de) 2012-01-09 2013-07-10 Universität Zürich Zellverkapselung mit hohem Durchsatz für Screening oder Auswahl
US9676849B2 (en) 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
LT2814843T (lt) 2012-02-13 2020-09-25 Agency For Science, Technology And Research ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
EP2814979A1 (de) 2012-02-17 2014-12-24 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Säugerhomologe von blumen, deren verwendung in der diagnose, vorbeugung und behandlung von krebs
EP3738980A1 (de) 2012-02-24 2020-11-18 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung des verschwindens von antigen mittels fc-gamma-riib
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
EP2857419B1 (de) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur beseitigung von aggregierten antigenen
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
WO2014001442A1 (en) * 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AR091774A1 (es) * 2012-07-16 2015-02-25 Dow Agrosciences Llc Proceso para el diseño de las secuencias de adn repetidas, largas, divergentes de codones optimizados
EP2692731A1 (de) * 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Rekombinante AAV-Vektorparitikel mit Liganden hoher Affinität für Zelltyp-spezifischen Gentransfer
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
BR112015006634B1 (pt) 2012-09-28 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Método e kit para avaliação de reação de coagulação sanguínea
EP2719706A1 (de) 2012-10-15 2014-04-16 Universität Zürich Bispezifische HER2-Liganden zur Krebstherapie
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
EP2738180A1 (de) 2012-11-30 2014-06-04 Molecular Partners AG Bindeproteine mit mindestens zwei Bindedomänen gegen HER2
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2961773B1 (de) 2013-02-26 2019-03-20 Roche Glycart AG Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP3566750A3 (de) 2013-02-28 2020-04-08 ImmunoGen, Inc. Konjugate aus zellbindenden und zytotoxischen verbindungen
CA2902068C (en) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105209483B (zh) * 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
PT3065761T (pt) 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
DK3078744T3 (da) 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
WO2015089585A1 (en) 2013-12-18 2015-06-25 Csl Limited Method of treating wounds
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20150092638A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p15 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150092637A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p16 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
EP3160990A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли
AU2015311987B2 (en) 2014-09-03 2020-06-04 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3224275B1 (de) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigenbindende moleküle mit einem ligandentrimer der tnf-familie
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
WO2016193497A1 (en) 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
CN107921094B (zh) 2015-06-04 2022-03-01 圣拉斐尔医院有限公司 Igfbp3及其用途
KR101713944B1 (ko) 2015-06-19 2017-03-09 한국과학기술원 신규한 혈관내피세포 성장인자와 결합할 수 있는 폴리펩타이드 및 이의 용도
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
UA120981C2 (uk) 2015-09-18 2020-03-10 Чугаі Сейяку Кабусікі Кайся Антитіло, що зв'язується з il-8, та його застосування
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AU2016330807B2 (en) 2015-10-02 2023-08-10 F. Hoffmann-La Roche Ag Anti-human CD19 antibodies with high affinity
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
US10597466B2 (en) 2015-12-02 2020-03-24 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
EP3243836A1 (de) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
KR102376582B1 (ko) 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
WO2018011405A1 (en) 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
MX2019003895A (es) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
EP4015532A1 (de) 2016-11-21 2022-06-22 cureab GmbH Anti-gp73-antikörper und immunkonjugate
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
AU2017380981B2 (en) 2016-12-19 2025-01-30 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
TWI781145B (zh) 2017-02-28 2022-10-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
CN110573528B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
EP3601346A1 (de) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispezifische antigenbindemoleküle für einen co-stimulierenden tnf-rezeptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
JP6997209B2 (ja) 2017-04-04 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０およびｆａｐに特異的に結合することができる新規な二重特異性抗原結合分子
EP4516809A3 (de) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispezifische antikörper mit spezifischer bindung an pd1 und lag3
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
EP3661536A4 (de) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
EP4512469A3 (de) 2017-09-11 2025-05-21 Monash University Bindung von proteinen an den menschlichen thrombinrezeptor par4
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
JP7793287B2 (ja) 2017-10-18 2026-01-05 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
BR112020007630A2 (pt) 2017-11-01 2020-11-17 F. Hoffmann-La Roche Ag anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
MY205342A (en) 2017-11-01 2024-10-16 Hoffmann La Roche Bispecific 2+1 contorsbodies
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
US11793885B2 (en) 2017-12-28 2023-10-24 Immunogen, Inc. Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
AU2019205090A1 (en) 2018-01-05 2020-08-06 Ac Immune Sa Misfolded TDP-43 binding molecules
EP3743448A4 (de) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. Xcr1-bindende wirkstoffe und verwendungen davon
EP3746470A1 (de) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilisierte immunoglobulindomänen
WO2019149716A1 (en) 2018-01-31 2019-08-08 F. Hoffmann-La Roche Ag Bispecific antibodies comprising an antigen-binding site binding to lag3
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
JP7350756B2 (ja) 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
JP7550647B2 (ja) 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
EP3623382A1 (de) 2018-09-14 2020-03-18 Universität Zürich Liganden zum gm-csf- oder gm-csf-rezeptor zur verwendung bei leukämie bei einem patienten mit einer allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3765489B1 (de) 2018-03-13 2024-10-16 F. Hoffmann-La Roche AG Therapeutische kombination von 4-1bb agonisten und anti-cd20 antikörper
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
EP3768833A1 (de) 2018-03-22 2021-01-27 Charité - Universitätsmedizin Berlin Crispr-assoziierte proteinreaktive t-zell-immunität
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
SG11202007961QA (en) 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
US12312383B2 (en) 2018-04-18 2025-05-27 Altius Institute For Biomedical Sciences Animal pathogen-derived polypeptides and uses thereof for genetic engineering
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
WO2019238966A1 (en) 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
US12264181B2 (en) 2018-06-27 2025-04-01 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
WO2020070041A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-fap clone 212
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
EP3632929A1 (de) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antikörper und verwendungen davon
BR112021005670A2 (pt) 2018-10-08 2021-06-22 Universität Zürich polipeptídeos tetraméricos de ligação a her2
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US20220017433A1 (en) 2018-11-21 2022-01-20 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
EP3677911A3 (de) 2019-01-03 2020-07-29 Universität Basel Verwendung von nicht-agonistische liganden zur unterdrückung von metastasen
EP3908274A1 (de) 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2-inhibitoren oder il-1r-antagonisten zur reduktion von hypoglykämie nach bariatrischer chirurgie
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
WO2020175502A1 (ja) 2019-02-27 2020-09-03 国立大学法人東京医科歯科大学 抗原結合タンパク質と蛍光タンパク質または蛍光標識されるタグタンパク質との融合タンパク質
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
CN113544509A (zh) 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
EP3943108A4 (de) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
JP7522100B2 (ja) 2019-04-02 2024-07-24 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
WO2020207771A1 (en) 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
JP7689373B2 (ja) 2019-04-18 2025-06-06 エイシー イミューン ソシエテ アノニム 治療及び診断のための新規分子
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
AU2020278907A1 (en) 2019-05-23 2022-01-20 Ac Immune Sa Anti-TDP-43 binding molecules and uses thereof
WO2020245746A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
JP7611173B2 (ja) 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
US20220253669A1 (en) 2019-06-07 2022-08-11 Chugai Seiyaku Kabushiki Kaisha Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
JP7691701B2 (ja) 2019-06-18 2025-06-12 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
US20220332845A1 (en) 2019-09-05 2022-10-20 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
WO2021094620A1 (en) 2019-11-15 2021-05-20 Enthera S.R.L. Tmem219 antibodies and therapeutic uses thereof
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
WO2021099484A1 (en) 2019-11-20 2021-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Archaeal peptide recombinase – a novel peptide ligating enzyme
US20230039165A1 (en) 2019-11-21 2023-02-09 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
CN115666594A (zh) 2019-11-29 2023-01-31 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP3868396A1 (de) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitoren und verwendungen davon
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230128499A1 (en) 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021204781A1 (en) 2020-04-06 2021-10-14 Universität Zürich Artc1 ligands for cancer treatment
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279309A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
WO2022029306A1 (en) 2020-08-07 2022-02-10 F. Hoffmann-La Roche Ag Method for producing protein compositions
TW202221026A (zh) 2020-08-14 2022-06-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
EP3957649A1 (de) 2020-08-18 2022-02-23 Athebio AG Verbesserte n-terminale kappungsmodule von ankyrinwiederholungsdomänen
IL300641A (en) 2020-08-18 2023-04-01 Univ Zuerich CD25 biased anti-IL-2 antibody
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
US20230391878A1 (en) 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
JP2023546112A (ja) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート
EP4229082A1 (de) 2020-10-16 2023-08-23 AC Immune SA Alpha-synuclein bindende antikörper zur therapie und diagnose
CN112230587B (zh) * 2020-10-29 2021-08-10 中国民用航空总局第二研究所 一种仪表着陆系统同频异呼运行监测系统及方法
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN117916261A (zh) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 与靶向fap的cd40激动剂的组合疗法
WO2022123459A1 (en) 2020-12-11 2022-06-16 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
EP4288455A1 (de) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Bindemittel und verfahren zur verwendung davon
US20240310378A1 (en) 2021-02-11 2024-09-19 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4305063A1 (de) 2021-03-09 2024-01-17 Molecular Partners AG Proteasespaltbare prodrugs
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
US20250076283A1 (en) 2021-05-19 2025-03-06 Chugai Seiyaku Kabushiki Kaisha Method for predicting in vivo pharmacokinetics of molecule
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
BR112024002196A2 (pt) 2021-08-05 2024-04-30 Immunos Therapeutics Ag Hla-b57 modificado com níveis de expressão aumentados
JP2024530040A (ja) 2021-08-05 2024-08-14 イムノス セラピューティクス アーゲー Ｈｌａ融合タンパク質を含む併用医薬
EP4384219A4 (de) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
EP4137508A1 (de) 2021-08-17 2023-02-22 Athebio AG Varianten von ankyrin-wiederholungsdomänen
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (de) 2021-10-08 2023-04-12 ETH Zurich Vorrichtung und verfahren zur manipulation von extrazellulären vesikeln
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022390134A1 (en) 2021-11-16 2024-05-16 Ac Immune Sa Novel molecules for therapy and diagnosis
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250382633A1 (en) 2021-12-21 2025-12-18 Universität Zürich Adenoviral vectors
CA3243689A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized Anti-TDP-43 Bonding Molecules and Their Uses
EP4499846A1 (de) 2022-03-25 2025-02-05 Universität Zürich Adenovirales targeting von aktivierten immunzellen
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
JPWO2023195515A1 (de) * 2022-04-06 2023-10-12
US20260043816A1 (en) 2022-04-08 2026-02-12 Ac Immune Sa Anti-TDP-43 Binding Molecules
EP4260907A1 (de) 2022-04-11 2023-10-18 Universität Zürich Mittel zum behandeln von endometriose und anderen gutartigen gynäkologischen neoplasmen
US20250223326A1 (en) 2022-05-10 2025-07-10 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
US20260061078A1 (en) 2022-08-31 2026-03-05 Universität Zürich Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
IL319568A (en) 2022-09-15 2025-05-01 Avidicure Ip B V Multispecific antigen-binding proteins for NK cell stimulation and their uses
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024074706A1 (en) 2022-10-07 2024-04-11 Universität Zürich Paracrine adenoviral delivery of biomolecules
EP4612178A1 (de) 2022-11-03 2025-09-10 F. Hoffmann-La Roche AG Kombinationstherapie mit bispezifischem anti-cd19/anti-cd28-antikörper
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
JP2026500369A (ja) 2022-12-19 2026-01-06 マックス－プランク－ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． 内因性凝縮体を標的とする手段及び方法
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
CN121002056A (zh) 2023-02-08 2025-11-21 免疫标记治疗股份公司 β2微球蛋白、HLA重链多肽、和CD47–SIRPα抑制剂的融合蛋白
EP4673159A1 (de) 2023-02-27 2026-01-07 Molecular Partners AG Darpine zur verwendung bei der reduzierung der nierenakkumulation von arzneimitteln
EP4676596A1 (de) 2023-03-08 2026-01-14 AC Immune SA Anti-tdp-43-bindende moleküle und verwendungen davon
EP4428159A1 (de) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanom-abzielende menschliche antikörper und ihre therapeutische verwendung
EP4428158A1 (de) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Gegen lungenkrebs gerichtete humane antikörper und therapeutische verwendungen davon
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
TW202502811A (zh) 2023-06-01 2025-01-16 瑞士商赫孚孟拉羅股份公司 與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子
EP4724486A1 (de) 2023-06-06 2026-04-15 Molecular Partners AG Rekombinante cd2-bindende proteine und deren verwendung
EP4724460A1 (de) 2023-06-06 2026-04-15 Molecular Partners AG Rekombinante cd16a-bindende proteine und deren verwendung
WO2024251695A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
KR20260026086A (ko) 2023-06-21 2026-02-25 에프. 호프만-라 로슈 아게 Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
CN121773137A (zh) 2023-07-05 2026-03-31 伯尔尼大学 用于治疗和预防脓毒症的IL-1Ra阻断剂
AU2024287547A1 (en) 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
CN121605481A (zh) 2023-08-10 2026-03-03 中外制药株式会社 信息处理系统、信息处理方法、程序和用于制造分子化合物的方法
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
EP4537907A1 (de) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248-inhibitoren und verwendungen davon
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025137687A2 (en) * 2023-12-22 2025-06-26 Conagen Inc. Production of peptides using tandem repetitive recombination strategy
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025163083A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recobminant dll3 binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026013280A1 (en) 2024-07-11 2026-01-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Designed ankyrin repeat proteins binding p53, and uses thereof
WO2026019692A2 (en) 2024-07-15 2026-01-22 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods
WO2026052650A1 (en) 2024-09-05 2026-03-12 F. Hoffmann-La Roche Ag Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
EP4729541A1 (de) 2024-10-16 2026-04-22 Paolo Fiorina Igfbp7-antikörper und verwendungen davon

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612340B2 (en) * 1986-11-04 1991-07-11 Protein Polymers Technologies, Inc. Construction of synthetic dna and its use in large polypeptide synthesis
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
DE19631106A1 (de) 1996-08-01 1998-02-05 Heinz Peter Brandstetter Statorplatte oder Statorelement
US5932440A (en) * 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP0975748B1 (de) 1997-04-23 2006-03-29 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
US5827692A (en) * 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
WO1999003494A1 (en) * 1997-07-18 1999-01-28 Yale University STRUCTURE OF THE ANKYRIN BINDING DOMAIN OF A ALPHA-Na,K-ATPase
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
DK1137941T4 (da) * 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US20020042094A1 (en) * 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
EP1266004A2 (de) * 2000-02-17 2002-12-18 Millennium Pharmaceuticals, Inc. Moleküle der pyrin domäne proteinfamilie und ihre anwendungen
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
AU2001278859A1 (en) * 2000-06-29 2002-01-14 University Of Florida Ubiquitin ligase

Also Published As

Publication number Publication date
DK1332209T3 (da) 2010-03-29
WO2002020565A2 (en) 2002-03-14
JP5291279B2 (ja) 2013-09-18
EP1332209A2 (de) 2003-08-06
DE60140474D1 (de) 2009-12-24
JP2013179942A (ja) 2013-09-12
AU2002218166A1 (en) 2002-03-22
US9006389B2 (en) 2015-04-14
US20120142611A1 (en) 2012-06-07
US9657287B2 (en) 2017-05-23
EP2149604A1 (de) 2010-02-03
US20150275201A1 (en) 2015-10-01
WO2002020565A3 (en) 2002-11-07
US20040132028A1 (en) 2004-07-08
US8110653B2 (en) 2012-02-07
US20090082274A1 (en) 2009-03-26
US7417130B2 (en) 2008-08-26
ES2335861T3 (es) 2010-04-06
EP1332209B1 (de) 2009-11-11
JP2016053031A (ja) 2016-04-14
CA2421447C (en) 2012-05-08
JP2004508033A (ja) 2004-03-18
CA2421447A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
ATE448301T1 (de) Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
DK0726955T3 (da) Kimære proteiner, som omfatter Borreliapolypeptider, og anvendelser heraf
EP1905829A3 (de) Templierte Moleküle und Verfahren zur Verwendung derartiger Moleküle
ATE205504T1 (de) Peptidnukleinsäuren
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1112101T1 (el) Νευροτροφικοι παραγοντες
BR0209989A (pt) Plataformas baseadas em cromossomas
ATE377220T1 (de) Verfahren zur erzeugung von passwörtern aus biometrischen daten
EP1453850A4 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
CY1109845T1 (el) Μεθοδος για τη συναρμολογηση πολυνουκλεοτιδιου διπλου-κλωνου
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE509103T1 (de) Neurotrophe faktoren
PT1341909E (pt) Metodo para a evolucao molecular in vitro da funcao de proteina
DE69534471D1 (de) Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
DE69734586D1 (de) Retinoid-metabolisierendes protein
ATE62256T1 (de) Durch quecksilberverbindungen katalisierte gruppenuebertragungspolymerisation.
HK1054572A1 (en) Method of generation and management of unique sequences in dna production
ES2187939T3 (es) Moleculas aisladas de acido nucleico codificantes de miembros de la familia ssx y utilizaciones de las mismas.
ATE208368T1 (de) Verfahren zur herstellung von 3,4 disubstituirten dinitroanilinen
ATE414905T1 (de) Diabetesmodell
BR9915537A (pt) Gene prv-1 e sua utilização
ATE305521T1 (de) Verfahren zur bindung von nukleinsäuren an einen träger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties